Wednesday 8th February 2023
January 2023 marked the 1st Anniversary of the SRUK STAR App. The data contained within the app helps facilitate research into Raynaud’s, allowing us to learn more about the condition and how it affects our community. Read on to find out more about the STAR App and what your data has shown us so far!
Friday 25th February 2022
Happy Raynaud's Awareness Month! In this week's article we take a closer look at some of the upcoming research focused on Raynaud's!
Friday 11th February 2022
A national trial is recruiting people with scleroderma to see how they have responded to their COVID-19 vaccinations. Have they produced antibodies?
Friday 4th February 2022
STAR is the newly upgraded app for tracking your Raynaud’ symptoms. The App was created to help you manage and record your attacks, all whilst contributing to valuable scientific research in just a few simple clicks.
Thursday 25th February 2021
A new study from the UK has identified a possible connection between metabolism and fibrosis in people with scleroderma, with the potential to open up new treatment avenues in the future.
Monday 10th February 2020
Despite Raynaud’s syndrome being a relatively common condition, with up to 10 million people in the UK diagnosed, several questions remain about the nature of the disease. We've addressed some of the most frequently asked ones here.
Tuesday 4th February 2020
With winter now upon us – a bad season for Raynaud’s patients – we asked members of our community for tips to avoid triggers and manage their symptoms.
Thursday 28th February 2019
Vitamin D deficiency has been linked to several autoimmune diseases, such as rheumatoid arthritis, lupus and multiple sclerosis, and is seen almost universally in patients with systemic sclerosis (SSc). This has garnered significant attention, alongside recent data suggesting that vitamin D plays a role in the functioning of the immune system.
Tuesday 26th February 2019
The results of a study spanning several years indicate that there may be long-term benefits of stem cell transplant in those suffering from severe scleroderma. This multi-centre study by researchers at Dartmouth, alongside other institutions, and led by Dr Jennifer Franks focused on comparing improvements in those treated with cyclophosphamide, the more conventional drug therapy for scleroderma, to those who had undergone a stem cell transplant.
Thursday 21st February 2019
Despite the drastic impact that Raynaud’s phenomenon can have on an individual’s quality of life, the detrimental effects that the condition may have on mental health are often overlooked.
